Researchers, including Ania M. Jastreboff, MD, PhD, detailed the results of a phase 2 study of maridebart cafraglutide for inducing weight loss in adults living with obesity, with or without type 2 diabetes.

Steven B. Heymsfield, MD, and other panelists discussed how bimagrumab can preserve the weight reduction seen with semaglutide while also improving body composition.

Vivian Fonseca, MD, and other investigators explained the results of the largest prospective study to date of hypercortisolism in difficult-to-treat diabetes and pharmacotherapy of hypercortisolism.

Researchers, including Viral N. Shah, MD, shared findings from phase 2 of the ADJUST-T1D study for the first time at the Scientific Sessions in Chicago. Once-weekly semaglutide enhanced the efficacy of automated insulin delivery alone in meeting time-in-range and weight-reduction targets.

Chantal Mathieu, MD, PhD, and other investigators reported on findings from three QWINT studies. Efsitora alfa is now the second long-acting, once-weekly insulin analog that has been evaluated in robust phase 3 studies and proven to be non-inferior to daily insulins.

Rodica Pop-Busui, MD, PhD, and other researchers shared new data showing oral semaglutide improved each of the composite measures of SOUL, death from cardiovascular causes, nonfatal stroke, and nonfatal myocardial infarction.

CORRECTION: Subodh Verma, MD, PhD, FRCSC, and others explained how semaglutide can change the trajectory of disease in individuals with type 2 diabetes and peripheral artery disease.

Experts discussed findings from two phase 3 studies that evaluated the efficacy of combined treatment with an amylin analog and a glucagon-like peptide 1 (GLP-1) receptor agonist in inducing weight loss in individuals living with obesity or overweight.

Speakers shared evidence of population-wide weight loss and improved use of weight-related treatment. Mark Gritz, PhD, said the goal was affordable care delivery that could be implemented broadly.

Julio Rosenstock, MD, shared data from ACHIEVE-1 that show orforglipron led to reductions in A1C and meaningful weight loss as monotherapy in drug-naïve type 2 diabetes with inadequate glycemic management.